Company intelligence / Profile preview

Enterprime

Ownership: Private
Development stage: Other

Overview

Enterprise Therapeutics' lead candidate, ETD001, targets the epithelial sodium channel in airway epithelium to increase hydration and clearance of mucus. A Phase 2a trial began in July 2024 for cystic fibrosis patients. The FDA granted rare pediatric designation to ETD001. Results from this study are expected in 2025. The company has raised significant funding (£26 million/$33.1 million Series B follow-on) to support ongoing trials and expanded its leadership team recently.

Therapeutic areas: Pulmonology
Modalities: Small molecule
Industry: Biotech

Partnerships

None publicly disclosed as of June 2024–June 2025.

Beyond the preview

Go deeper on Enterprime.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enterprime.

Explore the full profile